Arvinas
Price & Volume
Stats
See more52W Range | $5.90-$21 |
Market Cap | $893.4M |
Shares Short | 6M |
Financials
See moreRevenue (12 Mos) | $312.3M |
Revenue Growth (YoY) | -59.1% |
Gross Profit (12 Mos) | $312.3M |
Diluted EPS | -$0.81 |
News
See moreYahoo Finance • 20 days ago
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Yahoo Finance • 30 days ago
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Yahoo Finance • last month
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
Yahoo Finance • 2 months ago
Arvinas outlines plan for $100M share buyback and targets sub-$75M quarterly run rate amid pipeline expansion
About
CEO | Dr. John G. Houston Ph.D. |
CFO | Mr. Andrew R. Saik |
Address | 5 Science Park, New Haven, CT, United States, 06511 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 430 |
